{"id":62724,"date":"2026-03-02T19:06:02","date_gmt":"2026-03-02T18:06:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/"},"modified":"2026-03-02T19:06:02","modified_gmt":"2026-03-02T18:06:02","slug":"median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/","title":{"rendered":"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\neyonis\u00ae LCS commercial launch is ongoing in U.S. following FDA 510(k) clearance<\/li>\n<li>\nCE-marking regulatory process is on-going with a decision expected in Q2 2026 that could trigger commercial rollout of eyonis\u00ae LCS across Europe this year<\/li>\n<li>\nMedian eyonis\u00ae team will be at Booth #AI-16, AI Exhibition, Expo X1, to highlight clinical impact of eyonis\u00ae LCS in lung cancer screening<\/li>\n<li>\neyonis\u00ae LCS will also be featured in two AI Lightning Talk industry sessions and one research session<\/li>\n<\/ul>\n<p>SOPHIA ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/5\/Logo_Median.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/22\/Logo_Median.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/5\/Logo_Median.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/21\/Logo_Median.jpg\"><\/a><\/p>\n<p>\nMedian Technologies <i>(FR0011049824, ALMDT, \u201cMedian\u201d or the \u201cCompany\u201d)<\/i>, developer of eyonis\u00ae, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMDs) for early cancer diagnosis and a global leader in AI-based image analysis and central imaging services for oncology drug development, today announced that it will feature eyonis\u00ae LCS at the European Congress of Radiology (ECR) 2026 in Vienna, March 4\u20136, 2026.<\/p>\n<p>\nThe Median eyonis\u00ae team will welcome attendees at Booth #AI-16, AI Exhibition, Expo X1, from March 4 to March 7 (technical exhibition dates), to present the latest developments related to eyonis\u00ae Lung Cancer Screening (LCS), its AI-powered Software as a Medical Device (SaMD).<\/p>\n<p>\n<i>\u201cEarlier this month, Median Technologies received FDA 510(k) clearance for eyonis\u00ae LCS, marking a pivotal milestone in our mission to transform lung cancer screening through cutting-edge AI innovation. As we work toward the obtention of our CE marking for eyonis\u00ae LCS, with a decision expected in Q2 this year, we are preparing for the next step: bringing our technology into clinical practice across Europe and empowering clinicians with new tools to diagnose lung cancer earlier and more effectively,\u201d <\/i>said <b>Thomas Bonnefont, COO and CCO of the eyonis\u00ae Business Unit at Median Technologies.<\/b><\/p>\n<p>\nOn <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Fpress-releases%2Fmedian-technologies-receives-fda-510k-clearance-for-eyonis-lcs-the-first-ai-tech-based-detection-and-diagnosis-device-for-lung-cancer-screening%2F&amp;esheet=54436407&amp;newsitemid=20260302913442&amp;lan=en-US&amp;anchor=February+9%2C+2026&amp;index=1&amp;md5=b1debf068f78bd242976eaf8939ad593\" rel=\"nofollow\" shape=\"rect\">February 9, 2026<\/a>, Median announced that eyonis\u00ae LCS, its AI-based CADe\/CADx SaMD for lung cancer screening, received FDA 510(k) clearance for detection and characterization of parenchymal pulmonary nodules in low-dose CT (LDCT) scans. eyonis\u00ae LCS is the only medical device software capable of detecting and characterizing lung cancer in LDCT scans, achieving 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value (NPV) (manufacturer values calculated on a lung cancer screening reference population). eyonis\u00ae LCS helps clinicians identify suspicious findings at early stages, enhancing the efficiency and consistency of lung cancer screening programs.<\/p>\n<p>\nMedian continues to advance along the European regulatory pathway for eyonis\u00ae LCS and anticipates obtaining CE marking in Q2 2026.<\/p>\n<p>\n<i>\u201cWe are thrilled to showcase our innovative software as a medical device, eyonis\u00ae LCS\u2014a Class IIb end-to-end Medical Device Software (MDSW)\u2014to the European radiology community gathered in Vienna for ECR. eyonis\u00ae LCS is designed to assist radiologists in the detection and characterization of pulmonary parenchymal nodules and represents a significant leap forward in lung cancer screening,\u201d <\/i>Bonnefont added.<\/p>\n<p>\nMedian\u2019s eyonis\u00ae team will also hold multiple presentations at ECR:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Industry Presentation: <\/b>\u201c<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.myesr.org%2Fcourse%2Fai-lightning-talks-3-3%2F&amp;esheet=54436407&amp;newsitemid=20260302913442&amp;lan=en-US&amp;anchor=eyonis%26%23174%3B+LCS%3A+redefining+Lung+Cancer+Screening+with+AI&amp;index=2&amp;md5=9e0ff83f725ad591c5d5546830d74ba7\" rel=\"nofollow\" shape=\"rect\">eyonis\u00ae LCS: redefining Lung Cancer Screening with AI<\/a>\u201d<br \/>\n<br \/>Presenter: Stefania Baraghini, VP Marketing eyonis\u00ae &#8211; Median Technologies<br \/>\n<br \/>Session AI-IND 3 &#8211; AI Lightning Talks 3<br \/>\n<br \/>Wednesday, March 4 &#8211; 13:30 \u2013 14:30 CET<br \/>\n<br \/>AI Theatre, ACV Building Level -2<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Industry Presentation: <\/b>\u201c<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.myesr.org%2Fcourse%2Fai-lightning-talks-8-3%2F&amp;esheet=54436407&amp;newsitemid=20260302913442&amp;lan=en-US&amp;anchor=eyonis%26%23174%3B+LCS%3A+Transforming+Lung+Cancer+Screening+through+AI-powered+detection+%26amp%3B+diagnosis&amp;index=3&amp;md5=1d8f1abbeb529cc7fd23c3f4dc2a9f0b\" rel=\"nofollow\" shape=\"rect\">eyonis\u00ae LCS: Transforming Lung Cancer Screening through AI-powered detection &amp; diagnosis<\/a>\u201d<br \/>\n<br \/>Presenters:<b> <\/b>Stefania Baraghini, VP Marketing eyonis\u00ae &#8211; and Laurence Boy-Machefer, VP Regulatory Affairs eyonis\u00ae &#8211; Median Technologies<br \/>\n<br \/>Session AI-IND 8 &#8211; AI Lightning Talks 8<br \/>\n<br \/>Thursday, March 5 &#8211; 16:00 \u2013 17:00 CET<br \/>\n<br \/>AI Theatre, ACV Building Level -2<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Research Presentation: \u201c<\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.myesr.org%2Fcourse%2Fexploring-the-ai-radiomics-interface-in-lung-cancer%2F&amp;esheet=54436407&amp;newsitemid=20260302913442&amp;lan=en-US&amp;anchor=AI-Assistance+Improving+Lung+Nodule+Risk+Assessment+in+Lung+Cancer+Screening%3A+Results+from+RELIVE%2C+A+Multi-Reader+Multi-Case+Study+to+Evaluate+the+Performance+of+an+End-to-End+AI%2FML-based+CADe%2FCADx&amp;index=4&amp;md5=d6bac51c42cd5bbcc242a36224e782cd\" rel=\"nofollow\" shape=\"rect\">AI-Assistance Improving Lung Nodule Risk Assessment in Lung Cancer Screening: Results from RELIVE, A Multi-Reader Multi-Case Study to Evaluate the Performance of an End-to-End AI\/ML-based CADe\/CADx<\/a>\u201d<br \/>\n<br \/>Presenter:<b> <\/b>Charles Voyton, Associate Director Clinical Development \u2013 eyonis\u00ae<br \/>\n<br \/>Research Presentation Session: Artificial Intelligence and Imaging Informatics<br \/>\n<br \/>RPS 105 &#8211; Exploring the AI-radiomics interface in lung cancer<br \/>\n<br \/>Wednesday March 4 &#8211; 08:00 &#8211; 09:30 am CET<br \/>\n<br \/>ACV Research Stage 6, Vienna, Austria<\/li>\n<\/ul>\n<p>\n<b>About Median Technologies: <\/b>Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median&#8217;s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis\u00ae, an AI\/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mediantechnologies.com&amp;esheet=54436407&amp;newsitemid=20260302913442&amp;lan=en-US&amp;anchor=www.mediantechnologies.com&amp;index=5&amp;md5=970f7c66137b188355769b08a3b0bbf0\" rel=\"nofollow\" shape=\"rect\">www.mediantechnologies.com<\/a>.<\/p>\n<p>\n<b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance.<\/p>\n<p>\nThese forward-looking statements can often be identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates&#8221; or &#8220;plans&#8221; and any other similar expressions. Although Median&#8217;s management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.<\/p>\n<p>\nAll forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorit\u00e9 des March\u00e9s Financiers.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>MEDIAN TECHNOLOGIES<\/b><br \/><b>Emmanuelle Leygues<\/b><br \/>VP, Corporate Marketing &amp; Financial Communications<br \/>\n<br \/>+33 6 10 93 58 88<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;&#x6f;:&#101;&#109;&#x6d;&#x61;&#x6e;ue&#108;&#x6c;&#x65;&#x2e;le&#121;&#103;&#x75;&#x65;&#x73;&#64;&#109;&#101;&#x64;&#x69;&#x61;n&#116;&#101;&#x63;&#x68;&#x6e;ol&#111;&#x67;&#x69;&#x65;s&#46;&#99;&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x65;m&#x6d;&#97;n&#x75;&#101;&#x6c;&#x6c;e&#x2e;&#108;e&#x79;&#103;&#x75;&#101;s&#x40;&#109;e&#x64;&#105;&#x61;&#110;t&#x65;&#99;&#x68;&#x6e;o&#x6c;&#111;g&#x69;&#101;&#x73;&#x2e;c&#x6f;&#109;<\/a><\/p>\n<p>\n<b>Press \u2013 MAARC<\/b><br \/><b>Bruno Arabian<\/b><br \/>+33 6 87 88 47 26<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#105;l&#116;o&#x3a;b&#x72;u&#x6e;o&#x2e;a&#x72;a&#x62;i&#x61;n&#x40;m&#x61;a&#x72;&#99;&#x2e;&#102;&#x72;\" rel=\"nofollow\" shape=\"rect\">b&#114;&#117;&#x6e;&#x6f;&#46;a&#114;&#97;&#x62;&#x69;an&#64;&#109;&#x61;&#x61;rc&#46;&#x66;&#x72;<\/a><br \/><b>Nicolas Entz<\/b><br \/>+33 6 33 67 31 54<br \/>\n<br \/><a target=\"_blank\" href=\"mai&#108;&#116;&#111;&#58;&#x6e;&#x69;&#x63;&#x6f;&#x6c;&#x61;&#x73;&#46;en&#116;&#122;&#64;&#109;&#97;&#x61;&#x72;&#x63;&#x2e;&#x66;&#x72;\" rel=\"nofollow\" shape=\"rect\">ni&#99;&#111;&#108;&#x61;&#x73;&#x2e;&#x65;nt&#122;&#64;&#109;&#x61;&#x61;&#x72;&#x63;&#46;f&#114;<\/a><\/p>\n<p>\n<b>Investors &#8211; SEITOSEI ACTIFIN<\/b><br \/><b>Ghislaine Gasparetto<\/b><br \/>+33 6 85 36 76 81<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#103;h&#x69;&#115;l&#x61;&#105;n&#x65;&#46;g&#x61;&#115;p&#x61;&#114;e&#x74;&#116;o&#x40;&#115;e&#x69;&#116;o&#x73;&#101;i&#x2d;&#97;c&#x74;&#105;f&#x69;&#110;&#46;&#x63;&#111;m\" rel=\"nofollow\" shape=\"rect\">&#103;&#x68;i&#x73;&#x6c;&#97;&#x69;n&#101;&#x2e;&#103;&#x61;s&#112;&#x61;r&#x65;t&#116;&#x6f;&#64;&#x73;&#x65;&#105;&#x74;o&#115;&#x65;&#105;&#x2d;a&#99;&#x74;&#105;&#x66;i&#110;&#x2e;c&#x6f;&#x6d;<\/a><\/p>\n<p>\n<b>U.S. media \u2013 TODD STEIN COMMUNICATIONS<\/b><br \/><b>Todd Stein<\/b><br \/>+1 510.417.0612<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#116;&#111;:to&#x64;&#x64;&#x40;&#x74;&#111;&#100;dst&#x65;&#x69;&#x6e;&#x63;&#111;&#109;&#109;un&#x69;&#x63;&#x61;&#x74;&#105;&#111;&#110;s&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x74;&#111;&#x64;&#x64;&#64;&#x74;&#111;d&#x64;&#115;t&#x65;&#105;&#x6e;&#x63;o&#x6d;&#109;u&#x6e;&#105;c&#x61;&#116;&#x69;&#x6f;&#110;&#x73;&#x2e;c&#x6f;&#109;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>eyonis\u00ae LCS commercial launch is ongoing in U.S. following FDA 510(k) clearance CE-marking regulatory process is on-going with a decision expected in Q2 2026 that could trigger commercial rollout of eyonis\u00ae LCS across Europe this year Median eyonis\u00ae team will be at Booth #AI-16, AI Exhibition, Expo X1, to highlight clinical impact of eyonis\u00ae LCS &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62724","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Median Technologies to Showcase eyonis\u00ae LCS, Its AI\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"eyonis\u00ae LCS commercial launch is ongoing in U.S. following FDA 510(k) clearance CE-marking regulatory process is on-going with a decision expected in Q2 2026 that could trigger commercial rollout of eyonis\u00ae LCS across Europe this year Median eyonis\u00ae team will be at Booth #AI-16, AI Exhibition, Expo X1, to highlight clinical impact of eyonis\u00ae LCS ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T18:06:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/22\/Logo_Median.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\\\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology\",\"datePublished\":\"2026-03-02T18:06:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/\"},\"wordCount\":987,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260302913442\\\/en\\\/2735008\\\/22\\\/Logo_Median.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/\",\"name\":\"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\\\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260302913442\\\/en\\\/2735008\\\/22\\\/Logo_Median.jpg\",\"datePublished\":\"2026-03-02T18:06:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260302913442\\\/en\\\/2735008\\\/22\\\/Logo_Median.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260302913442\\\/en\\\/2735008\\\/22\\\/Logo_Median.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\\\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/","og_locale":"en_US","og_type":"article","og_title":"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology - Pharma Trend","og_description":"eyonis\u00ae LCS commercial launch is ongoing in U.S. following FDA 510(k) clearance CE-marking regulatory process is on-going with a decision expected in Q2 2026 that could trigger commercial rollout of eyonis\u00ae LCS across Europe this year Median eyonis\u00ae team will be at Booth #AI-16, AI Exhibition, Expo X1, to highlight clinical impact of eyonis\u00ae LCS ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-02T18:06:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/22\/Logo_Median.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology","datePublished":"2026-03-02T18:06:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/"},"wordCount":987,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/22\/Logo_Median.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/","url":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/","name":"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/22\/Logo_Median.jpg","datePublished":"2026-03-02T18:06:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/22\/Logo_Median.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260302913442\/en\/2735008\/22\/Logo_Median.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-to-showcase-eyonis-lcs-its-ai-ml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Median Technologies to Showcase eyonis\u00ae LCS, Its AI\/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62724"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62724\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}